| Literature DB >> 21190589 |
Ratana Banjerdpongchai1, Prachya Kongtawelert, Orawan Khantamat, Chantragan Srisomsap, Daranee Chokchaichamnankit, Pantipa Subhasitanont, Jisnuson Svasti.
Abstract
BACKGROUND: Zearalenone (ZEA) is a phytoestrogen from Fusarium species. The aims of the study was to identify mode of human leukemic cell death induced by ZEA and the mechanisms involved.Entities:
Mesh:
Substances:
Year: 2010 PMID: 21190589 PMCID: PMC3018374 DOI: 10.1186/1756-8722-3-50
Source DB: PubMed Journal: J Hematol Oncol ISSN: 1756-8722 Impact factor: 17.388
Figure 1Structure of zearalenone (ZEA; 6-[10-hydroxy-oxo-trans-1-undecenyl]-B-resorcyclic acid lactone).
Primer Sequences Used for Real-time Reverse Transcription Polymerase Chain Reaction.
| Gene | Sequences (5'-3') | GenBank accession number |
|---|---|---|
| GRP78 | Forward: GCCTGTATTTCTAGACCTGCC | |
| CRT | Forward: AAATGAGAAGAGCCCCGTTCTTCCT | |
| ERp29 | Forward: CCTGAAGATCATGGGGAAGA | |
| GAPDH | Forward: GAAGGTGAAGGTCGGAGTC | |
Figure 2Effect of ZEA on cell cytotoxicity and apoptotic induction of human leukemic HL-60 and U937 cells. (A) Cell viability of HL-60, U937 and human peripheral blood mononuclear cells using MTT assay. (B) DNA cell cycle analysis of HL-60 and U937 cells treated with ZEA for 24 h. * p < 0.05, compared with control cells. (C) and (D) Histograms of HL-60 and U937 cells treated with ZEA at indicated concentrations, respectively. Cells were stained with PI and subjected to flow cytometer as described in Materials and methods. M1, subdiploid; M2, G1; M3, G2 M.
Figure 3Mitochondria-mediated human leukemic cell apoptosis. Reduction of mitochondrial transmembrane potential of HL-60 (A) and U937 (B) cells treated with ZEA. Cells were stained with 40 nM DiOC6 for 15 min and then subjected to flow cytometry. Cells with decreased mitochondrial transmembrane potential are less stained with DiOC6. (C) Release of cytochrome c from mitochondria. HL-60 cells were treated with ZEA (10, 50 μg/ml) for 4 h and cytosolic cytochrome c was detected by Western blotting. Representative data from three independent experiments are shown.
Figure 4Expression of Bax, Bcl-2 and Bcl-xL in ZEA-treated HL-60 cells. Bax, Bcl-2 and Bcl-xL expression (A) and the ratio of Bax/Bcl-xL (B) are from the same sample of cells. Representative data from three independent experiments are shown. The density of bands are plotted as ratio of Bax/Bcl-xL and the results are mean ± S.E.M. from three independent experiments. *, p < 0.05, compared to control.
Figure 5Generation by ZEA of reactive oxygen species (ROS) in HL-60 cells. HL-60 cells were treated with 20 μg/ml ZEA for 4 h, incubated with 5 μM DCFH-DA for 15 min and subjected to flow cytometry. Histograms from flow cytometry are shown and cells with increased fluorescence are designated as M1, indicating the presence of ROS.
Figure 6Effect of zearalenone (ZEA) on activation of caspase-3 and caspase-8. Activity of caspase-3 and caspase-8 of HL-60 (A) and U937 (B) cells treated for 24 h with various concentrations of ZEA were measured using specific substrate analogs as described in Materials and methods. Data represent mean values ± S.E.M. from three independent experiments. *, p < 0.05, compared to control.
Figure 7Two-dimensional polyacrylamide gel-electrophoresis pattern of U937 and HL-60 cells. (A) U937 cells cultured for 4 and 24 h in the presence or absence of ZEA. (a) control 4 h cells, (b) control 24 h cells, (c) cells treated with 6 μg/ml ZEA for 4 h, (d) cells treated with 6 μg/ml ZEA for 24 h. (Arrow 1) fructose bisphosphate aldolase A, muscle type, lung cancer antigen NY LU1, (arrow 2 and 3) glyceraldehyde 3-phosphate dehydrogenase, (arrow 4) deoxyuridine triphosphate nucleotidohydrolase, mitochondrial precursor. (B) HL-60 cell cultured for 24 h with (right panel) and without ZEA (left panel). There are 22 protein dots of different expression in plasma membrane. The list of proteins identified by LC/MS/MS is shown in Table 1.
Identified Plasma Membrane Protein Spots in 24 h ZEA-treated HL-60 Cells by LC/MS/MS.
| Spot no. | Protein Name(s) | Description | MW/pI | Peptide match | % Coverage | Sequence | *Expression in treated cells (folds) |
|---|---|---|---|---|---|---|---|
| 1 | TERA_HUMAN | Transitional endoplasmic reticulum ATPase | 89.3/5.18 | - | - | - | -1.99 |
| 2 | GFAP_HUMAN | Glial fibrillary acidic protein | 49.8/5.25 | 1 | 2.55 | (K)LALDIEIATYR(K) | -1.55 |
| K2C8_HUMAN | Keratin, type II cytoskeletal 8 | 53.7/5.34 | 1 | 2.28 | |||
| HS90A_HUMAN | Heat shock protein HSP 90-alpha | 83.2/4.97 | 7 | 10.00 | K.IDIIPNPQER.T | ||
| 3 | GRP78_HUMAN | 78 kDa glucose-regulated protein precursor (GRP 78) | 72.3/5.10 | - | - | - | 1.93 |
| 4 | PLSL_HUMAN | L-plastin, Lymphocyte cytosolic protein 1 | 70.2/5.02 | 11 | 22.01 | (K)AACLPLPGYR(V) | -3.1 |
| 5 | CALR_HUMAN | Calreticulin precursor | 60.6/4.37 | - | - | - | 2.39 |
| 6 | PDIA1_HUMAN | Protein disulfide isomerase precursor | 51.1/4.78 | - | - | - | 2.86 |
| 7 | EF2_HUMAN | Elongation factor 2 | 95.1/6.78 | - | - | - | -2.87 |
| 8 | gi|28317 | unnamed protein product | 59.5/5.17 | 3 | 6.00 | R.ALEESNYELEGK.I | 2.26 |
| 9 | DHSA_HUMAN | Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial | 72.6/7.04 | 4 | 8.43 | (R)AAFGLSEAGFNTACVTK(L) | -1.29 |
| TCPG_HUMAN | T-complex protein 1 subunit gamma | 60.5/6.06 | 1 | 2.02 | (K)TAVETAVLLLR(I) | ||
| 10 | SERA_HUMAN | D-3-phosphoglycerate dehydrogenase | 56.6/6.28 | 1 | 2.44 | (K)GTIQVITQGTSLK(N) | -1.34 |
| TCPZ_HUMAN | T-complex protein 1 subunit zeta | 58.0/6.22 | 1 | 2.26 | (K)GIDPFSLDALSK(E) | ||
| gi|4502643 | chaperonin containing TCP1, subunit 6A isoform a | 58.0/6.23 | 7 | 15.00 | R.AQAALAVNISAAR.G | ||
| gi|1002923 | coronin-like protein | 51.0/6.12 | 7 | 15.00 | R.HVFGQPAK.A | ||
| 11 | 119623333 | apoptosis inducing factor like isoform CRA d Homo sapiens | 63.7/10.23 | 1 | 1.21 | (R)LLSATSR(T) | 2.18 |
| RN112_HUMAN | RING finger protein 112 | 68.3/8.45 | 1 | 1.11 | (R)LSGRYPK(V) | ||
| gi|4557014 | catalase [Homo sapiens] | 59.7/6.90 | 12 | 28.00 | K.ADVLTTGAGNPVGDK.L | ||
| gi|28317 | unnamed protein product | 59.5/5.17 | 7 | 14.00 | R.ALEESNYELEGK.I | ||
| 12 | SAM50_HUMAN | Sorting and assembly machinery component 50 homolog | 51.9/6.46 | 5 | 14.50 | (K)VNQELAGYTGGDVSFIK(E) | -1.98 |
| gi|7022134 | unnamed protein product | 51.9/6.62 | 9 | 20.00 | K.DVVVQHVHFDGLGR.T | ||
| gi|4929571 | CGI-51 protein | 52.1/6.85 | 10 | 26.00 | K.DVVVQHVHFDGLGR.T | ||
| ANX11_HUMAN | Annexin A11 | 54.3/7.53 | 5 | 11.00 | R.GTITDAPGFDPLR.D | ||
| 13,14 | ENOA_HUMAN | Alpha-enolase | 47.0/7.54 | - | - | - | -1.57, |
| 15 | 119571303 | spectrin domain with coiled coils 1 isoform CRA d Homo sapiens | 28.9/4.97 | 1 | 4.20 | (R)LQIVSLASWAR(A) | 5.14 |
| ATPG_HUMAN | ATP synthase subunit gamma, mitochondrial | 33.0/9.56 | 1 | 4.03 | (R)IYGLGSLALYEK(A) | ||
| TPM3_HUMAN | Tropomyosin alpha-3 chain | 32.8/4.49 | 1 | 2.82 | (K)HIAEEADR(K) | ||
| ES8L1_HUMAN | Epidermal growth factor receptor kinase substrate 8-like protein 1 | 80.3/5.66 | 1 | 0.69 | (K)SGPSR(K) | ||
| gi|16877071 | ATP synthase, H+ transporting, mitochondrial F1 complex, gamma polypeptide 1 | 32.9/9.23 | 3 | 11.00 | R.IYGLGSLALYEK.A | ||
| 16 | LDHB_HUMAN | L-lactate dehydrogenase B chain | 36.6/5.64 | 2 | 8.08 | (K)SLADELALVDVLEDK(L) | -1.62 |
| AFF4_HUMAN | AF4/FMR2 family member 4 | 12.7/9.68 | 1 | 0.77 | (K)NSSSTSKQK(K) | ||
| 17 | COMT_HUMAN | Catechol O-methyltransferase | 30.0/5.12 | 2 | 14.02 | (K)VTLVVGASQDIIPQLK(K) | 1.07 |
| PODXL_HUMAN | Podocalyxin like protein 1 precursor | 55.6/5.23 | 1 | 2.46 | (R)LASVPGSQTVVVK(E) | ||
| 121944562 | immunoglobulin A heavy chain variable region Homo sapiens | 11.9/5.64 | 1 | 5.50 | (K)VDGIEK(Y) | ||
| TRM13_HUMAN | tRNA guanosine-2'-O-methyltransferase TRM13 homolog | 54.2/8.01 | 1 | 2.49 | (R)KTSLETSNSTTK(R) | ||
| 18 | ANXA1_HUMAN | Annexin A1 | 38.7/6.63 | 5 | 22.00 | K.GGPGSAVSPYPTFNPSSDVAALHK.A | 3.25 |
| CN102_HUMAN | UPF0614 protein C14orf102 | 13.2/7.60 | 1 | 0.52 | (R)LISLAK(C) | ||
| 19 | SOCS4_HUMAN | Suppressor of cytokine signaling 4 | 50.6/6.64 | 1 | 1.36 | (R)SDLAFR(W) | -3.12 |
| K2C1_HUMAN | Keratin, type II cytoskeletal 1(CK-1) | 65.8/8.16 | 4 | 5.00 | R.QFSSR.S | ||
| K2C7_HUMAN | Keratin, type II cytoskeletal 7 (CK-7) | 51.2/5.50 | 1 | 2.00 | K.LALDIEIATYR.K | ||
| 20 | gi|189054178 | unnamed protein product [Homo sapiens] | 66.0/7.62 | 4 | 6.00 | R.SLDLDSIIAEVK.A | -2.84 |
| 21 | AF047368_1 | nebulette Homo sapiens | 11.6/7.98 | 1 | 0.99 | (K)ENQGNISSVK(Y) | 2.99 |
| ERp29_HUMAN | Endoplasmic reticulum protein ERp29 | 29.0/6.77 | 7 | 22.00 | K.GALPLDTVTFYK.V | ||
| 22 | ATP5H_HUMAN | ATP synthase subunit d, mitochondrial | 18.5/5.21 | 6 | 40.00 | K.TIDWVAFAEIIPQNQK.A | -1.08 |
| gi|189054178 | unnamed protein product | 66.0/7.62 | 3 | 5.00 | K.SLNNQFASFIDK.V | ||
| 23 | B2MG_HUMAN | Beta-2 microglobulin | 12.7/5.77 | 2 | 18.00 | R.VNHVTLSQPK.I | 1.35 |
| 24 | NDUBA_HUMAN | NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 10 | 20.8/8.60 | 3 | 20.35 | (K)AFDLIVDRPVTLVR(E) | -1.05 |
| gi|189054178 | unnamed protein product | 65.9/7.62 | 7 | 12.00 | R.TNAENEFVTIK.K | ||
| 25 | ASCC1_HUMAN | Activating signal cointegrator 1 complex subunit 1 | 45.48/5.22 | 1 | 1.75 | (R)SFALLPR(L) | 1.11 |
| PHB_HUMAN | prohibitin | 29.8/5.57 | 11 | 52.00 | K.FGLALAVAGGVVNSALYNVDAGHR.A | ||
| 26 | PHB_HUMAN | Prohibitin | 29.8/5.57 | 13 | 59.00 | K.VFESIGK.F | 1.06 |
| NDUS3_HUMAN | NADH dehydrogenase [ubiquinone] iron-sulfur protein 3, mitochondrial | 30.2/6.99 | 2 | 9.00 | K.SLVDLTAVDVPTR.Q | ||
Note: Spot no. 1, 3, 5, 7, 13 and 14 were matched from our hepatocellular carcinoma cell line database. *The density of spots were calculated as percent volume and shown in this table as folds of increase or decrease (-).
Figure 8Real-time reverse transcription polymerase chain reaction of . HL-60 cells were treated with 20 μg/ml ZEA for indicated time of incubation. The levels of mRNA were normalized to the level of GAPDH mRNA. After the normalization, the mRNA level was expressed as the fold change compared to that in the basal group untreated with ZEA (at 0 h). Data are the mean ± S.E.M. of three independent experiments. * p < 0.05 compared to control, # p < 0.01 compared to control.
Figure 9Effect of ZEA on cytosolic (A) and mitochondrial (B) Ca. HL-60 cells were incubated with Fluo3 (cytosolic) or Rhod2 (mitochondrial) Ca2+- specific dye for 15 min after treatment with and without ZEA for 1 h, then were subjected to flow cytometry as described in Materials and Methods. Black trace, control cells; red trace, ZEA-treated cells. Histogram of FACS analysis represents one of three independent experiments.
Figure 10Cell surface exposure of calreticulin in ZEA-treated HL-60 cells. Cells were treated for 30 min with ZEA at indicated concentrations and analyzed for the caltreticulin exposure by flow cytometry as described in Materials and Methods. Histogram of FACS analysis represents one of three independent experiments.